Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2338

1.

Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.

Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.

Medicine (Baltimore). 2018 Nov;97(47):e13341. doi: 10.1097/MD.0000000000013341.

2.

Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials.

Wang YK, Zhang YM, Qin SQ, Wang X, Ma T, Guo JB, Zhu C, Luo ZJ.

Medicine (Baltimore). 2018 Oct;97(42):e12691. doi: 10.1097/MD.0000000000012691. Review.

3.

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis.

Khanizadeh F, Rahmani A, Asadollahi K, Ahmadi MRH.

Arch Endocrinol Metab. 2018 Aug;62(4):438-445. doi: 10.20945/2359-3997000000060.

4.

Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.

Zhu J, Huo Q, Xu M, Yang F, Li Y, Shi H, Niu Y, Liu Y.

Nanoscale. 2018 Oct 4;10(38):18387-18397. doi: 10.1039/c8nr03899f.

PMID:
30256367
5.

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.

Medicine (Baltimore). 2018 Aug;97(31):e11694. doi: 10.1097/MD.0000000000011694.

6.
7.

Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.

Inoue Y, Mitsunaga K, Yamamoto T, Chiba K, Yamaide F, Nakano T, Morita Y, Yamaide A, Suzuki S, Arima T, Yamaguchi KI, Tomiita M, Shimojo N, Kohno Y.

Pediatr Rheumatol Online J. 2018 Jun 18;16(1):36. doi: 10.1186/s12969-018-0258-5.

8.

Betti number ratios as quantitative indices for bone morphometry in three dimensions.

Teramoto T, Kamiya T, Sakurai T, Kanaya F.

Comput Methods Programs Biomed. 2018 Aug;162:93-98. doi: 10.1016/j.cmpb.2018.05.012. Epub 2018 May 5.

PMID:
29903498
10.

Development and Evaluation of Liquid and Solid Lipid Based Drug Delivery Systems Containing Technetium-99m-Radiolabeled Alendronate Sodium.

Gundogdu E, Ekinci M, Ozgenc E, Ozdemir DI, Asikoglu M.

Curr Radiopharm. 2018;11(2):100-108. doi: 10.2174/1874471011666180529111914.

PMID:
29807525
11.

[Catgut implantation at stellate ganglion for postmenopausal osteoporosis].

Gu Z, Liang P, Xie S.

Zhongguo Zhen Jiu. 2018 May 12;38(5):4993-502. doi: 10.13703/j.0255-2930.2018.05.012. Chinese.

PMID:
29797914
12.

Design and development of novel hyaluronate-modified nanoparticles for combo-delivery of curcumin and alendronate: fabrication, characterization, and cellular and molecular evidences of enhanced bone regeneration.

Dong J, Tao L, Abourehab MAS, Hussain Z.

Int J Biol Macromol. 2018 Sep;116:1268-1281. doi: 10.1016/j.ijbiomac.2018.05.116. Epub 2018 May 18.

PMID:
29782984
13.

A retrospective study of alendronate for the treatment of ankylosing spondylitis.

Li G, Lv CA, Tian L, Jin LJ, Zhao W.

Medicine (Baltimore). 2018 May;97(20):e10738. doi: 10.1097/MD.0000000000010738.

14.

The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.

Chiu WY, Yang WS, Chien JY, Lee JJ, Tsai KS.

PLoS One. 2018 Apr 25;13(4):e0196419. doi: 10.1371/journal.pone.0196419. eCollection 2018.

15.

Effects of polycaprolactone on alendronate drug release from Mg-doped hydroxyapatite coating on titanium.

Bose S, Vu AA, Emshadi K, Bandyopadhyay A.

Mater Sci Eng C Mater Biol Appl. 2018 Jul 1;88:166-171. doi: 10.1016/j.msec.2018.02.019. Epub 2018 Feb 24.

PMID:
29636132
16.

Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.

Ilyas A, Hashim Z, Channa IS, Zarina S.

Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):241-250. doi: 10.1016/j.hbpd.2018.03.013. Epub 2018 Mar 24.

PMID:
29627155
17.

The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.

Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T.

PLoS One. 2018 Mar 15;13(3):e0193846. doi: 10.1371/journal.pone.0193846. eCollection 2018.

18.

Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature.

McCadden L, Leonard CG, Primrose WJ.

J Laryngol Otol. 2018 Apr;132(4):372-374. doi: 10.1017/S0022215118000324. Epub 2018 Feb 28. Review.

PMID:
29486808
19.

ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.

Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X.

Endocr Pract. 2018 Feb;24(2):179-188. doi: 10.4158/EP171910.OR.

PMID:
29466057
20.

Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.

Açil Y, Arndt ML, Gülses A, Wieker H, Naujokat H, Ayna M, Wiltfang J.

J Craniomaxillofac Surg. 2018 Apr;46(4):538-546. doi: 10.1016/j.jcms.2017.12.015. Epub 2018 Jan 10.

PMID:
29454604

Supplemental Content

Loading ...
Support Center